Benzinga | May 3, 2021 04:12PM EDT

Cardiovascular Systems Highlights Publication Of Article In 'Journal Of Medical Economics' Reviewing 2-Year Health Care Costs Of Patients Enrolled In LIBERTY 360 Trial

Cardiovascular Systems, Inc. (CSI(r)) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that a new article published in the Journal of Medical Economics reviews the two-year PAD-related health care costs of patients enrolled in the LIBERTY 360? trial.

LIBERTY 360? represents the largest, contemporary real-world experience with various endovascular strategies across the full range of Rutherford Class (RC) patients, including those with critical limb ischemia, the most compromised RC6 patients.

In the article, "Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360? trial" by Elizabeth A. Magnuson, et al., the authors note that among patients with symptomatic lower extremity PAD undergoing endovascular revascularization, initial treatment costs and total 2-year costs varied significantly according to clinical and lesion-level characteristics, as well as symptom burden.

Said Scott Ward, CSI's Chairman, President and Chief Executive Officer, "Data from the LIBERTY 360? study revealed high freedom from major amputation out to three years (RC2-3, 98.5%; RC4-5, 94.0%; and RC6, 79.9%). And the orbital atherectomy sub analysis of this data indicated high freedom from major amputation (RC2-3, 100%; RC4-5, 95.3%; and RC6, 88.6%) with no additional amputations reported after the two-year visit. These data are especially compelling in the context of cost analyses showing that the durable patient outcomes from the use of orbital atherectomy resulted in lower mean cumulative PAD-related costs one- and two-years after the procedure."

LIBERTY 360? (OAS RC2-6) 2-Year Costs

Orbital atherectomy (RC2-6; N=503) mean index procedure cost was $11,729 and by two-years the mean costs were $29,474, numerically lower than the overall LIBERTY (RC2-6; N=1189) mean two-year cost of $30,491.

PAD-related costs ($) up to 2 years following the index procedure

All Any Orbital All Any Orbital Patients Atherectomy Patients Atherectomy

11,621 11,729IndexHospitalization (11,189 (11,165 to to 12,443) 18,870 17,745 12,081) Years 1+2 follow-up (17,046 (15,113 to 11,741 10,976 to 20,835) 20,802)Year 1 follow-up (10,597 (9,344 to to 12,741) 12,974)

7,476 6,911 11,465 10,806Endovascular Endovascularprocedures (6,730 to (5,758 to procedures (10,321 8,944 to 8,263) 8,127) to 12,916) 12,688)

1,625 1,698 2,077 1,987Surgical Surgicalprocedures 1,218 to (1,096 to procedures (1,616 to (1,353 to 2,041) 2,384) 2,569) 2,708)

140 115 193 128Other PAD Other PADhospitalizations (74 to (34 to 231) hospitalizations (113 to (41 to 251) 211) 278)

2,501 2,253 5,134 4,824Outpatient/ Outpatient/chronic care (2,011 to (1,586 to chronic care (4,041 to (3,272 to 3,000) 3,126) 6,253) 6,791)

23,362 22,706 30,491 29,474Cumulative Cumulative1-year (22,110 (20,998 to 2-year (28,569 (26,655 to to 24,627) to 32,665) 24,623) 32,506)

Magnuson EA, et al. J Med Econ. 2021 April 18:1